This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, C.-I.
Right arrow Articles by Choe, K.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, C.-I.
Right arrow Articles by Choe, K.-W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4574-4581, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4574-4581.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Bloodstream Infections Due to Extended-Spectrum ß-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy

Cheol-In Kang,1 Sung-Han Kim,1 Wan Beom Park,1 Ki-Deok Lee,1 Hong-Bin Kim,1 Eui-Chong Kim,2,3 Myoung-Don Oh,1,3* and Kang-Won Choe1,3

Departments of Internal Medicine,1 Laboratory Medicine, Seoul National University College of Medicine,2 Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea3

Received 13 January 2004/ Returned for modification 24 April 2004/ Accepted 29 August 2004

This study was conducted to evaluate risk factors for mortality and treatment outcome of bloodstream infections due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK). ESBL production in stored K. pneumoniae and E. coli blood isolates from Jan 1998 to Dec 2002 was phenotypically determined according to NCCLS guidelines and/or the double-disk synergy test. A total of 133 patients with ESBL-EK bacteremia, including 66 patients with ESBL-producing K. pneumoniae and 67 with ESBL-producing E. coli, were enrolled. The overall 30-day mortality rate was 25.6% (34 of 133). Independent risk factors for mortality were severe sepsis, peritonitis, neutropenia, increasing Acute Physiology and Chronic Health Evaluation II score, and administration of broad-spectrum cephalosporin as definitive antimicrobial therapy (P < 0.05 for each of these risk factors). In 117 of the 133 patients, excluding 16 patients who died within 3 days after blood culture sample acquisition, the 30-day mortality rates according to definitive antibiotics were as follows: carbapenem, 12.9% (8 of 62); ciprofloxacin, 10.3% (3 of 29); and others, such as cephalosporin or an aminoglycoside, 26.9% (7 of 26). When patients who received appropriate definitive antibiotics, such as carbapenem or ciprofloxacin, were evaluated, mortality in patients receiving inappropriate empirical antimicrobial therapy was found not to be significantly higher than mortality in those receiving appropriate empirical antimicrobial therapy (18.9 versus 15.5%; P = 0.666). Carbapenem and ciprofloxacin were the most effective antibiotics in antimicrobial therapy for ESBL-EK bacteremia. A delay in appropriate definitive antimicrobial therapy was not associated with higher mortality if antimicrobial therapy was adjusted appropriately according to the susceptibility results. Our data suggest that more prudent use of carbapenem as empirical antibiotic may be reasonable.

* Corresponding author. Mailing address: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong Chongno-gu, Seoul 110-744, Republic of Korea. Phone: 82-2-760-2945. Fax: 82-2-762-9662. E-mail address: mdohmd{at}snu.ac.kr.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4574-4581, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4574-4581.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., Peters, C., Ahsan, M., Chateau, D., the Cooperative Antimicrobial Therapy of Septic Sh, (2009). Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock. Chest 136: 1237-1248 [Abstract] [Full Text]  
  • Dashti, A A, Jadaon, M M, Habeeb, F M (2009). Can we rely on one laboratory test in detection of extended-spectrum {beta}-lactamases among Enterobacteriaceae? An evaluation of the Vitek 2 system and comparison with four other detection methods in Kuwait. J. Clin. Pathol. 62: 739-742 [Abstract] [Full Text]  
  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Calatayud, L., Arnan, M., Linares, J., Dominguez, M. A., Gudiol, C., Carratala, J., Batlle, M., Ribera, J. M., Gudiol, F. (2008). Prospective Study of Fecal Colonization by Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli in Neutropenic Patients with Cancer. Antimicrob. Agents Chemother. 52: 4187-4190 [Abstract] [Full Text]  
  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Tumbarello, M., Sali, M., Trecarichi, E. M., Leone, F., Rossi, M., Fiori, B., De Pascale, G., D'Inzeo, T., Sanguinetti, M., Fadda, G., Cauda, R., Spanu, T. (2008). Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrob. Agents Chemother. 52: 3244-3252 [Abstract] [Full Text]  
  • Lin, M. Y., Weinstein, R. A., Hota, B. (2008). Delay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe Neutropenia. Antimicrob. Agents Chemother. 52: 3188-3194 [Abstract] [Full Text]  
  • Nicasio, A. M., Kuti, J. L., Aslanzadeh, J., Nicolau, D. P. (2008). Influence of automated screening and confirmation of extended-spectrum {beta}-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol 57: 1147-1151 [Abstract] [Full Text]  
  • Vasilev, K., Reshedko, G., Orasan, R., Sanchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., Orrico, R., Ellis-Grosse, E., on behalf of the 309 Study Group, (2008). A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62: i29-i40 [Abstract] [Full Text]  
  • (2008). Risks of extended-spectrum beta-lactamases. DTB 46: 21-24 [Abstract] [Full Text]  
  • Hall, R. G., Shah, S. R., Villela, L. R., Amirkhan, R. H. (2007). Impact of Inadequate Empiric Antimicrobial Therapy on Clinical Outcomes of Patients With Escherichia coli or Klebsiella Species Bacteremia. Journal of Pharmacy Practice 20: 392-398 [Abstract]  
  • Peralta, G., Sanchez, M. B., Garrido, J. C., De Benito, I., Cano, M. E., Martinez-Martinez, L., Roiz, M. P. (2007). Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 60: 855-863 [Abstract] [Full Text]  
  • Yang, K., Guglielmo, B J. (2007). Diagnosis and Treatment of Extended-Spectrum and AmpC {beta}-Lactamase-Producing Organisms. The Annals of Pharmacotherapy 41: 1427-1435 [Abstract] [Full Text]  
  • Livermore, D. (2007). The zeitgeist of resistance. J Antimicrob Chemother 60: i59-i61 [Abstract] [Full Text]  
  • Turnidge, J., Paterson, D. L. (2007). Setting and Revising Antibacterial Susceptibility Breakpoints. Clin. Microbiol. Rev. 20: 391-408 [Abstract] [Full Text]  
  • Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., Spanu, T. (2007). Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment. Antimicrob. Agents Chemother. 51: 1987-1994 [Abstract] [Full Text]  
  • Scarsi, K. K., Feinglass, J. M., Scheetz, M. H., Postelnick, M. J., Bolon, M. K., Noskin, G. A. (2006). Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.. Antimicrob. Agents Chemother. 50: 3355-3360 [Abstract] [Full Text]  
  • Spanu, T., Sanguinetti, M., Tumbarello, M., D'Inzeo, T., Fiori, B., Posteraro, B., Santangelo, R., Cauda, R., Fadda, G. (2006). Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates.. J. Clin. Microbiol. 44: 3257-3262 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Gavin, P. J., Suseno, M. T., Thomson, R. B. Jr., Gaydos, J. M., Pierson, C. L., Halstead, D. C., Aslanzadeh, J., Brecher, S., Rotstein, C., Brossette, S. E., Peterson, L. R. (2006). Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella Species.. Antimicrob. Agents Chemother. 50: 2244-2247 [Abstract] [Full Text]  
  • Tumbarello, M., Spanu, T., Sanguinetti, M., Citton, R., Montuori, E., Leone, F., Fadda, G., Cauda, R. (2006). Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome. Antimicrob. Agents Chemother. 50: 498-504 [Abstract] [Full Text]  
  • Paterson, D. L., Bonomo, R. A. (2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 18: 657-686 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»